NephCure Kidney International ®

Saving Kidneys, Saving Lives

  • Find a Specialist
  • Find a Clinical Trial
  • Donate
  • Living with Kidney Disease
    • Understanding Kidney Disease
    • Understanding Nephrotic Syndrome and Glomerular Disease
    • Treatment Options
    • Managing Your Care
    • Diet and Nutrition
    • Resources A-Z
    • Educational Programs
    • End Stage Renal Disease
    • Just for Kids!
  • Patient Connections
    • Patient Stories
    • Share Your Story
    • NephSpace – Our Online Support Community
    • Patient Support
  • Events
  • Get Involved
    • Join Your Local Community
    • Participate in Research
    • Advocacy
    • Peer Support
    • Donate
  • Research
    • Get Involved in Research
    • Conferences and Meetings
    • Apply for Research Grants
  • About Us
    • Recent News
    • Funded Research
    • Staff
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Partners
  • Donate
    • One Time Donation
    • Give Monthly
    • Donate to an Event

A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

This study will determine the effectiveness of a compound called ACH-0144471 at improving the clinical symptoms of C3G of IC-MPGN. Patients will participate for 1 year. ACH-0144471 is an oral tablet that study participants will take daily. Additional study visits and diagnostic tests may be required, including biopsies and labwork.

How To Contact a Study Center:

  • Visit KidneyHealthGateway.com to see if you might be eligible and to contact a study site near you

Research

  • NephCure Funded Research
  • Participate in Research
    • The Liposorber Trial for Adults with FSGS
    • The Liposorber Trial for Pediatric Patients with FSGS
    • The PROTECT Trial for IgAN Patients
    • The NefIgArd Study
    • AURONA
    • A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
    • OMS721 for Patients with IgAN
    • An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
    • Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients
    • The PODO Trial
    • Phoenix Trial for FSGS
    • DUPLEX - Sparsentan in FSGS
    • FIRSTx (ENROLLMENT COMPLETE)
    • The PODO Trial
    • The Discovery Trial
  • Clinical Trial FAQs
  • Conferences and Meetings
  • Apply for Research Grants

Our Mission

NephCure Kidney International’s ® mission is to accelerate research for effective treatments for rare forms of Nephrotic Syndrome, and to provide education and support that will improve the lives of those affected by these protein-spilling kidney diseases.

Sign up for our emails »

NephCure Kidney International

  • Contact Us
  • Donate
  • Careers
  • Financials
  • Policy and Disclaimers

SHORT ON TIME?

Contact Information

150 S. Warner Road
Suite 402
King of Prussia, PA 19406
1.866 NephCure (637-4287)
info@nephcure.org
EIN: 38-3569922

Follow Us

  • Facebook
  • Twitter

© Copyright 2021 NephCure Kidney International, Inc. All rights reserved worldwide. NephCure Kidney International, and the logo, are federally registered trademarks of NephCure Kidney International, Inc.

Copyright © 2021 · Outreach Pro Theme on Genesis Framework · WordPress · Log in